Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Now Rated “Hold” by Wall Street Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus rating of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $11.50.

Several research firms have recently issued reports on KPTI. Rodman & Renshaw lowered shares of Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, November 2nd. Piper Sandler reduced their price target on Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st. Royal Bank Of Canada reissued an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. Finally, Robert W. Baird lowered Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research report on Friday, July 31st.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KPTI. Commodore Capital LP acquired a new position in shares of Karyopharm Therapeutics in the 1st quarter valued at about $10,862,000. Avidity Partners Management LP boosted its holdings in shares of Karyopharm Therapeutics by 244.6% during the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock worth $2,583,000 after purchasing an additional 329,175 shares during the period. Context Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the third quarter worth approximately $322,000. Squarepoint Ops LLC purchased a new position in Karyopharm Therapeutics during the second quarter valued at approximately $623,000. Finally, Headlands Technologies LLC purchased a new position in Karyopharm Therapeutics during the second quarter valued at approximately $118,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Stock Performance

KPTI traded down $0.00 on Friday, reaching $0.02. 121,835,945 shares of the company’s stock were exchanged, compared to its average volume of 24,322,726. Karyopharm Therapeutics has a twelve month low of $0.02 and a twelve month high of $10.99. The company’s 50 day moving average is $0.85 and its 200-day moving average is $5.69. The company has a market cap of $362,880.00, a price-to-earnings ratio of -0.00 and a beta of 1.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The business had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $32.19 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -4.05 EPS for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Founded in 2008 and headquartered in Newton, Massachusetts, the company’s research centers on blocking nuclear export, a process that can help cancer cells survive and grow. Its lead product is selinexor, marketed in the United States as Xpovio. The oral therapy is approved for certain adults with multiple myeloma, including use in combination with other medicines. Karyopharm is also developing selinexor and other drug candidates for additional cancers.